| Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas KC Schreck, S Ranjan, N Skorupan, C Bettegowda, CG Eberhart, ... Journal of neuro-oncology 143 (1), 87-93, 2019 | 105 | 2019 |
| A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas N Skorupan, MI Ahmad, SM Steinberg, JB Trepel, D Cridebring, H Han, ... Future Oncology 18 (20), 2475-2481, 2022 | 22 | 2022 |
| Clinical strategies targeting the tumor microenvironment of pancreatic ductal adenocarcinoma N Skorupan, M Palestino Dominguez, SL Ricci, C Alewine Cancers 14 (17), 4209, 2022 | 17 | 2022 |
| Trends in grade 5 toxicity and response in phase I trials in hematologic malignancy: 20-year experience from the Cancer Therapy Evaluation Program at the National Cancer Institute D Chihara, EP Huang, SR Finnigan, LM Cordes, N Skorupan, Y Fukuda, ... Journal of Clinical Oncology 40 (17), 1949-1957, 2022 | 7 | 2022 |
| Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists N Skorupan, S Ranjan, S Mehta, O Yankulina, N Nenortas, S Grossman, ... Neuro-Oncology Practice 6 (4), 321-326, 2019 | 7 | 2019 |
| Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? N Skorupan, S Ghabra, JA Maldonado, Y Zhang, C Alewine Journal of cancer metastasis and treatment 9, 2023 | 5 | 2023 |
| Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment X Zhang, Y Yu, CJ Peer, R Landsman, N Skorupan, L Cao, C Alewine Translational Oncology 21, 101440, 2022 | 4 | 2022 |
| Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer. N Skorupan, MI Ahmad, GJ Pegna, CJ Peer, JB Trepel, MJ Lee, S Lee, ... Journal of Clinical Oncology 39 (15_suppl), 3051-3051, 2021 | 3 | 2021 |
| Pharmacological analysis of the rat femoral artery response to bradykinin M Radenković, M Stojanović, N Skorupan, M Prostran Scientia Pharmaceutica 81 (3), 749, 2013 | 3 | 2013 |
| Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health D Chihara, EP Huang, SR Finnigan, LM Cordes, N Skorupan, YK Fukuda, ... Blood 136, 18, 2020 | 2 | 2020 |
| Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology S Ranjan, N Skorupan, X Ye, A Sivakumar, O Yankulina, D Kamson, ... Neuro-Oncology Practice 7 (1), 52-58, 2020 | 2 | 2020 |
| Metabolički odgovor na test fizičkog opterećenja kod fizički aktivnih i neaktivnih ispitanika R Jeremić, A Bjelić, N Skorupan Medicinski podmladak 63 (1-2), 74-77, 2012 | 2 | 2012 |
| Incidence and Natural History of H3 K27M-mutated Midline Gliomas in Adults (S30. 001) K Schreck, S Ranjan, N Skorupan, M Holdhoff, H Ames Neurology 92 (15_supplement), S30. 001, 2019 | 1 | 2019 |
| Phase I study of ProAgio, an αvβ3 integrin cytotoxin, in patients with previously treated advanced pancreatic cancer and other solid tumors. N Skorupan, KT Schmidt, E Koehler, MJ Lee, SM Steinberg, WD Figg, ... Journal of Clinical Oncology 42 (16_suppl), e16336-e16336, 2024 | | 2024 |
| Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers N Skorupan, CJ Peer, X Zhang, H Choo-Wosoba, MI Ahmad, MJ Lee, ... Frontiers in Oncology 14, 2024 | | 2024 |
| Phase I trial of avbeta3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies N Skorupan, CJ Peer, E Koehler, S Steinberg, JB Trepel, WD Figg, ZR Liu, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies N Skorupan, CJ Peer, E Koehler, S Steinberg, JB Trepel, WD Figg, ZR Liu, ... Molecular Cancer Therapeutics 22 (12_Supplement), B047-B047, 2023 | | 2023 |
| Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib. N Skorupan, CJ Peer, Y Yu, MJ Lee, S Lee, S Rastogi, N Sato, ... Journal of Clinical Oncology 41 (16_suppl), e15017-e15017, 2023 | | 2023 |
| Abstract PO-054: A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP) N Skorupan, MI Ahmad, SM Steinberg, JB Trepel, D Cridebring, H Han, ... Cancer Research 81 (22_Supplement), PO-054-PO-054, 2021 | | 2021 |
| PATH-35. FREQUENCY AND CHARACTERISTICS OF H3K27M-MUTATION IN ADULTS WITH RADIOGRAPHICALLY-DETERMINED MIDLINE GLIOMAS K Schreck, S Ranjan, N Skorupan, H Ames, M Holdhoff Neuro-Oncology 20 (Suppl 6), vi166, 2018 | | 2018 |
Matthias HoldhoffJohns Hopkins University在 jhmi.edu 的电子邮件经过验证
